P/E ratio for Avadel Pharmaceuticals (AVDL)
P/E ratio as of April 2024 (TTM): -8.56
According to Avadel Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.5625. At the end of 2022 the company had a P/E ratio of -3.13.
P/E ratio history for Avadel Pharmaceuticals from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -3.13 | -48.92% |
| 2021 | -6.12 | -114.66% |
| 2020 | 41.8 | -592.15% |
| 2019 | -8.48 | 738.45% |
| 2018 | -1.01 | -120.11% |
| 2017 | 5.03 | -151.32% |
| 2016 | -9.80 | -178.67% |
| 2015 | 12.5 | -279.65% |
| 2014 | -6.94 | 45.6% |
| 2013 | -4.76 | -107.94% |
| 2012 | 60.0 | -514.75% |
| 2011 | -14.5 | 3.47% |
| 2010 | -14.0 | -11.16% |
| 2009 | -15.7 | 100.83% |
| 2008 | -7.84 | 24.12% |
| 2007 | -6.32 | -68.58% |
| 2006 | -20.1 | 27.76% |
| 2005 | -15.7 | -148.44% |
| 2004 | 32.5 | -138.8% |
| 2003 | -83.7 | -148.35% |
| 2002 | 173 | -1245.83% |
| 2001 | -15.1 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -4.67 | -45.50% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | -0.9953 | -88.38% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.